Outsourcing

Contract-service providers are expanding their offerings in this slow-growth environment.

Personalized medicine and integrated healthcare delivery require new business and pricing models. This article contains bonus online-exclusive material.

Select contract manufacturing organizations roll out expansions for production of active pharmaceutical ingredients and intermediates.

As new process validation guidelines emerge, industry needs to reinvent how it releases product.

IPEC's new stability testing guide takes into account the full supply chain's storage conditions.

The author reviews the major biopharmaceutical markets' activity and predicts how the markets may evolve.

Scientists from DSM and Kaneka discuss various techniques in this roundtable moderated by Patricia Van Arnum.

Quanticate's Commercial Director explains the ins and outs of outsourcing.

In the current slow growth environment, service providers are looking to tactical expansions, as well as more ambitious strategic service expansions.

Increase your chances of success in the biggest market in the world.

Belgium is one of the largest centres for pharmaceutical distribution and has the second highest number of pharma exports per capita worldwide.

Eastern Europe's pharmaceutical market is forecast to grow at a CAGR of more than 10% to be worth more than $41 billion by 2014, according to a report from companiesandmarkets.com.

Company and People Notes: UCB and Novartis form agreement; AAIPharma appoints VP of regulatory affairs; more...

Only 43% of European Chief Financial Officers (CFOs) and Chief Information Officers (CIOs) have tried to calculate the impact of outsourcing on their company, and of those that have tried, only 1 in 5 are confident in their sums, according to a study by Cognizant.

Also, FDA publishes draft guidances of two ICH Annexes; EMEA sets format for compliance advice; more...

India accounts for approximately 3% of the global outsourcing market, which indicates a significant opportunity for growth, according to a report published by Ernst and Young and the Organization of Pharmaceutical Producers of India.

Only 43% of European chief financial officers (CFOs) and chief information officers (CIOs) have tried to calculate the impact of outsourcing on their company, and of those that have tried, only 1 in 5 are confident about their calculations, according to a study by Cognizant, a global business technology company based in Teaneck, NJ.

Also, XCELERON and GSK form agreement; Millipore appoints VP of life sciences; more...

Also: DSM's North Carolina facility receives SafeBridge certification; Dynavax CFO to retire; more...

The US Food and Drug Administration released its Guidance for Industry titled Pharmaceutical Components at Risk for Melamine Contamination.

Soelkner discusses the latest industry developments and trends.

Also, Pfizer forms two research agreements in China; NanoInk appoints John Kubricky to its scientific advisory board; more...

As the pharmaceutical industry looks to emerging markets, corruption becomes an important issue.

Brief pharmaceutical news items for August 2009.

Biotech firms must first close the gaps between science and biology on the path toward QbD.

Individuals and companies at the top seem to have no problem short-circuiting their success.

Determined to prevent further supply-chain breaches, industry takes charge, offers proposals.

As the pharmaceutical supply chain expands, sponsor companies need to weigh all their options.

The contract services industry may not be as robust in 2009 as it has been in previous years, but it's not as bad as many people think.

A roundtable with pharma majors Pfizer and Johnson & Johnson, moderated by Jim Miller.